ID

44314

Description

Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC; ODM derived from: https://clinicaltrials.gov/show/NCT00755534

Link

https://clinicaltrials.gov/show/NCT00755534

Keywords

Versions (2)
  1. 12/28/17 12/28/17 -
  2. 9/20/21 9/20/21 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

September 20, 2021

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Colorectal Cancer NCT00755534

English

Eligibility Colorectal Cancer NCT00755534

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically confirmed locally advanced or metastatic colorectal cancer
Description

Colorectal Cancer Advanced Locally | Colorectal cancer metastatic

Data type

boolean

Alias
UMLS CUI [1,1]
C0009402
UMLS CUI [1,2]
C0205179
UMLS CUI [1,3]
C1517927
UMLS CUI [2]
C0948380
measurable or evaluable disease according to the response evaluation criteria in solid tumors (recist)
Description

Measurable Disease | Evaluable Disease

Data type

boolean

Alias
UMLS CUI [1]
C1513041
UMLS CUI [2]
C1516986
ecog performance status ≤ 2
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
age 18 - 72 years
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
patients who have had a cr, pr or sd after 1st line therapy based on irinotecan+bevacizumab
Description

In complete remission Post First line treatment | Partial response Post First line treatment | Stable Disease Post First line treatment | irinotecan | bevacizumab

Data type

boolean

Alias
UMLS CUI [1,1]
C0677874
UMLS CUI [1,2]
C0687676
UMLS CUI [1,3]
C1708063
UMLS CUI [2,1]
C1521726
UMLS CUI [2,2]
C0687676
UMLS CUI [2,3]
C1708063
UMLS CUI [3,1]
C0677946
UMLS CUI [3,2]
C0687676
UMLS CUI [3,3]
C1708063
UMLS CUI [4]
C0123931
UMLS CUI [5]
C0796392
paraffin block from the primary tumor in order to perform tha mutational analysis of the kras gene
Description

Paraffin Block Primary tumor | KRAS gene targeted mutation analysis

Data type

boolean

Alias
UMLS CUI [1,1]
C1519524
UMLS CUI [1,2]
C0677930
UMLS CUI [2]
C4264276
adequate liver (bilirubin ≤ 1.5 upper normal limit, sgot/sgpt ≤ 4 upper normal limit, alp ≤ 2.5 upper normal limit),renal (creatinine ≤ 1.5 upper normal limit) and bone marrow (anc ≥ 1,500/mm3, plt ≥100,000/mm3) function
Description

Liver function | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Alkaline phosphatase measurement | Renal function | Creatinine measurement, serum | Bone Marrow function | Absolute neutrophil count | Platelet Count measurement

Data type

boolean

Alias
UMLS CUI [1]
C0232741
UMLS CUI [2]
C1278039
UMLS CUI [3]
C0201899
UMLS CUI [4]
C0201836
UMLS CUI [5]
C0201850
UMLS CUI [6]
C0232804
UMLS CUI [7]
C0201976
UMLS CUI [8,1]
C0005953
UMLS CUI [8,2]
C0031843
UMLS CUI [9]
C0948762
UMLS CUI [10]
C0032181
patients must be able to understand the nature of this study
Description

Comprehension Study Protocol

Data type

boolean

Alias
UMLS CUI [1,1]
C0162340
UMLS CUI [1,2]
C2348563
written informed consent
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
presence of central nervous system or brain metastases
Description

CNS metastases | Metastatic malignant neoplasm to brain

Data type

boolean

Alias
UMLS CUI [1]
C0686377
UMLS CUI [2]
C0220650
pregnant or lactating woman
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
life expectancy < 3 months
Description

Life Expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0023671
previous radiotherapy within the last 4 weeks or > 25% of bone marrow or in the field where the treatment target is located
Description

Prior radiation therapy | Therapeutic radiology procedure Bone Marrow Percentage | Radiotherapy, Targeted

Data type

boolean

Alias
UMLS CUI [1]
C0279134
UMLS CUI [2,1]
C1522449
UMLS CUI [2,2]
C0005953
UMLS CUI [2,3]
C0439165
UMLS CUI [3]
C0205918
peripheral neuropathy grade ≥2
Description

Peripheral Neuropathy CTCAE Grades

Data type

boolean

Alias
UMLS CUI [1,1]
C0031117
UMLS CUI [1,2]
C1516728
known hypersensitivity to erbitux
Description

Hypersensitivity Erbitux

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1173436
metastatic infiltration of the liver >50%
Description

Infiltration metastatic Liver Percentage

Data type

boolean

Alias
UMLS CUI [1,1]
C0332448
UMLS CUI [1,2]
C1522484
UMLS CUI [1,3]
C0023884
UMLS CUI [1,4]
C0439165
patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction or total colectomy
Description

Chronic diarrhea | Partial bowel obstruction | Total colectomy

Data type

boolean

Alias
UMLS CUI [1]
C0401151
UMLS CUI [2]
C1328480
UMLS CUI [3]
C0192871
active infection
Description

Communicable Disease

Data type

boolean

Alias
UMLS CUI [1]
C0009450
second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer
Description

Second Primary Cancers | Exception Skin carcinoma | Exception Carcinoma in situ of uterine cervix

Data type

boolean

Alias
UMLS CUI [1]
C0751623
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0699893
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0851140
psychiatric illness or social situation that would preclude study compliance
Description

Mental disorders Exclude Protocol Compliance | Social situation Excludes Protocol Compliance

Data type

boolean

Alias
UMLS CUI [1,1]
C0004936
UMLS CUI [1,2]
C0332196
UMLS CUI [1,3]
C0525058
UMLS CUI [2,1]
C0748872
UMLS CUI [2,2]
C0332196
UMLS CUI [2,3]
C0525058
Back to the top of the page

Similar models

Eligibility Colorectal Cancer NCT00755534

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Colorectal Cancer Advanced Locally | Colorectal cancer metastatic
Item
histologically confirmed locally advanced or metastatic colorectal cancer
boolean
C0009402 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C1517927 (UMLS CUI [1,3])
C0948380 (UMLS CUI [2])
Measurable Disease | Evaluable Disease
Item
measurable or evaluable disease according to the response evaluation criteria in solid tumors (recist)
boolean
C1513041 (UMLS CUI [1])
C1516986 (UMLS CUI [2])
ECOG performance status
Item
ecog performance status ≤ 2
boolean
C1520224 (UMLS CUI [1])
Age
Item
age 18 - 72 years
boolean
C0001779 (UMLS CUI [1])
In complete remission Post First line treatment | Partial response Post First line treatment | Stable Disease Post First line treatment | irinotecan | bevacizumab
Item
patients who have had a cr, pr or sd after 1st line therapy based on irinotecan+bevacizumab
boolean
C0677874 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C1708063 (UMLS CUI [1,3])
C1521726 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C1708063 (UMLS CUI [2,3])
C0677946 (UMLS CUI [3,1])
C0687676 (UMLS CUI [3,2])
C1708063 (UMLS CUI [3,3])
C0123931 (UMLS CUI [4])
C0796392 (UMLS CUI [5])
Paraffin Block Primary tumor | KRAS gene targeted mutation analysis
Item
paraffin block from the primary tumor in order to perform tha mutational analysis of the kras gene
boolean
C1519524 (UMLS CUI [1,1])
C0677930 (UMLS CUI [1,2])
C4264276 (UMLS CUI [2])
Liver function | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Alkaline phosphatase measurement | Renal function | Creatinine measurement, serum | Bone Marrow function | Absolute neutrophil count | Platelet Count measurement
Item
adequate liver (bilirubin ≤ 1.5 upper normal limit, sgot/sgpt ≤ 4 upper normal limit, alp ≤ 2.5 upper normal limit),renal (creatinine ≤ 1.5 upper normal limit) and bone marrow (anc ≥ 1,500/mm3, plt ≥100,000/mm3) function
boolean
C0232741 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
C0201850 (UMLS CUI [5])
C0232804 (UMLS CUI [6])
C0201976 (UMLS CUI [7])
C0005953 (UMLS CUI [8,1])
C0031843 (UMLS CUI [8,2])
C0948762 (UMLS CUI [9])
C0032181 (UMLS CUI [10])
Comprehension Study Protocol
Item
patients must be able to understand the nature of this study
boolean
C0162340 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
Informed Consent
Item
written informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
CNS metastases | Metastatic malignant neoplasm to brain
Item
presence of central nervous system or brain metastases
boolean
C0686377 (UMLS CUI [1])
C0220650 (UMLS CUI [2])
Pregnancy | Breast Feeding
Item
pregnant or lactating woman
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Life Expectancy
Item
life expectancy < 3 months
boolean
C0023671 (UMLS CUI [1])
Prior radiation therapy | Therapeutic radiology procedure Bone Marrow Percentage | Radiotherapy, Targeted
Item
previous radiotherapy within the last 4 weeks or > 25% of bone marrow or in the field where the treatment target is located
boolean
C0279134 (UMLS CUI [1])
C1522449 (UMLS CUI [2,1])
C0005953 (UMLS CUI [2,2])
C0439165 (UMLS CUI [2,3])
C0205918 (UMLS CUI [3])
Peripheral Neuropathy CTCAE Grades
Item
peripheral neuropathy grade ≥2
boolean
C0031117 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
Hypersensitivity Erbitux
Item
known hypersensitivity to erbitux
boolean
C0020517 (UMLS CUI [1,1])
C1173436 (UMLS CUI [1,2])
Infiltration metastatic Liver Percentage
Item
metastatic infiltration of the liver >50%
boolean
C0332448 (UMLS CUI [1,1])
C1522484 (UMLS CUI [1,2])
C0023884 (UMLS CUI [1,3])
C0439165 (UMLS CUI [1,4])
Chronic diarrhea | Partial bowel obstruction | Total colectomy
Item
patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction or total colectomy
boolean
C0401151 (UMLS CUI [1])
C1328480 (UMLS CUI [2])
C0192871 (UMLS CUI [3])
Communicable Disease
Item
active infection
boolean
C0009450 (UMLS CUI [1])
Second Primary Cancers | Exception Skin carcinoma | Exception Carcinoma in situ of uterine cervix
Item
second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer
boolean
C0751623 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0699893 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0851140 (UMLS CUI [3,2])
Mental disorders Exclude Protocol Compliance | Social situation Excludes Protocol Compliance
Item
psychiatric illness or social situation that would preclude study compliance
boolean
C0004936 (UMLS CUI [1,1])
C0332196 (UMLS CUI [1,2])
C0525058 (UMLS CUI [1,3])
C0748872 (UMLS CUI [2,1])
C0332196 (UMLS CUI [2,2])
C0525058 (UMLS CUI [2,3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial